MKI67 and breast carcinoma: Tumor cell proliferation rate, often assessed via MKI67 (Ki-67) IHC, is a well-established adverse prognostic feature for many tumor types such as breast cancer (3) and gastrointestinal neuroendocrine tumors (4).